- Country profiles
- Data dashboard
- Satellite Pages
- About us
- WHAT'S NEW
The Hong Kong STD/AIDS update is a composite report on HIV/AIDS reporting and STI caseload statistics published 3 monthly. The current issue has the updated information up to December 2018.
The HIV surveillance system in Hong Kong comprises 5 main programmes to provide a detailed description of the local HIV/AIDS situation. They are (a) voluntary HIV/AIDS case-based reporting; (b) HIV prevalence surveys; (c) sexually transmitted infections (STI) caseload statistics; (d) behavioral studies; and (e) HIV-1 genotyping studies. All data are collected, analysed and disseminated regularly by the surveillance team of Special Preventive Programme (SPP), Centre for Health Protection (CHP), Department of Health(DH). At present, the latest HIV/AIDS statistics are released at quarterly intervals at press media briefings and in electronic format (http://www.aids.gov.hk). Data from various sources are compiled annually and released in this report.
This guidance note builds on UNDP’s Strategic Plan 2018–2021 which recognizes UNDP as an integrator to support “greater collaboration across sectors and partners to deliver impacts at scale and to utilize limited resources efficiently.” The guidance note also build on UNDP’s HIV, Health and Development Strategy 2016–2021 which stresses the need for “innovative approaches that harness synergies across the goals […] particularly given the need to make the most efficient and effective use of available development resources."
The Global Fund to Fight AIDS, TB and Malaria has opened up the opportunity to incorporate tobacco control into TB and HIV grants. In line with the 2030 Agenda, the UNDP Strategic Plan 2018-2021, and UNDP’s HIV, Health and Development Strategy 2016-21: Connecting the Dots, UNDP and the Secretariat of the WHO Framework Convention on Tobacco Control (WHO FCTC) have produced this Issue Brief to inform Global Fund applicants on integrating tobacco cessation into Global Fund HIV and TB grants. The Issue Brief outlines how tobacco consumption worsens TB and HIV outcomes and how the integration of tobacco control could increase health benefits and efficiencies. Key approaches and practical options for such integration are outlined, based on a review of research and case studies.
Keywords: TB, HIV, SDGs, response, tobacco
In 2017, key populations (KP) and their sexual partners accounted for approximately 40% of new HIV infections globally (UNAIDS, 2018). A range of policy and legal barriers and harmful social dynamics increase the HIV vulnerability of KP and undermine their access to HIV and other services. The criminalization of sex between men, sex work, drug use and HIV transmission, as well as high rates of incarceration, homophobia, trans phobia, violence and social marginalization, all serve to influence risk practices and undermine access to services. People from key populations often migrate to cities in search of safer and more secure communities (UNAIDS, UN Habitat 2015). Women in key populations face specific challenges and barriers, including gender-based violence (GBV) and poorly tailored services. These factors further intensify their vulnerability to HIV.
The Universal Periodic Review (UPR), alongside other international and national human rights mechanisms, is an important tool for holding countries that are part of the United Nations, known as UN Member States, accountable for respecting, promoting and fulfilling the human rights of people who use drugs, as well as fulfilling the pledges countries have made through the Sustainable Development Goals (SDGs). The UPR has the potential to improve human rights everywhere, for everyone. Countries can use it to initiate national human rights processes, and it can provide a valuable opportunity for civil society to engage governments on issues relating to human rights in the context of drug policies and people who use drugs.
This practitioners Toolkit on Women’s Access to Justice, developed by UNDP, UN Women, UNODC, and OHCHR provides evidence-based guidance for a coherent and consistent policy and programming approach to overcoming these obstacles. This guidance will help to ensure UN system coordinated responses when addressing legal and justice challenges that women face within the context areas of marriage, family, and property rights; ending violence against women; and women in conflict with the law. Designed primarily for staff of the UN system, the toolkit presents a menu of options for scaling-up work and responding to current deficits in women’s access to justice programming and the growing demand for technical assistance in this area. This toolkit consolidates and complements existing resources and aims at enhancing the impact of UN support by stimulating bolder gender-responsive justice interventions for the full realization of the rights of women and girls.
The Joint United Nations Programme on HIV/AIDS (UNAIDS) leads and inspires the world to achieve its shared vision of zero new HIV infections, zero discrimination and zero AIDSrelated deaths and to end the AIDS epidemic as a public health threat as a contribution to achieving the Sustainable Development Goals. A champion and forerunner of United Nations reform, UNAIDS unites the efforts of 11 United Nations Cosponsors—UNHCR, UNICEF, WFP, UNDP, UNFPA, UNODC, UN Women, ILO, UNESCO, WHO and the World Bank—and the UNAIDS Secretariat. The achievement of sustainable results for people is at the centre of the Joint Programme’s operations at all levels.
The world drug problem has multiple public health dimensions encompassing vulnerability to drug use disorders and dependence, treatment and care of people with drug use disorders, reducing harm associated with drug misuse, and access to controlled medicines for medical pain relief.
In partnership with the UN Office on Drugs and Crime (UNODC), which is recognized as the leading UN entity for countering the world drug problem, the World Health Organization (WHO) has a pivotal and unique role in addressing the public health and human rights dimensions of global issues related to drugs.
WHO estimates that 71 million people worldwide were chronically infected with hepatitis C virus (HCV) in 2017. Globally, 23% of new HCV infections and one in three HCV deaths are attributable to injecting drug use (PWID). HCV is also a major concern for people detained in prisons and other closed settings – available data demonstrate that one in four detainees are HCV positive.
This policy brief highlights the current landscape of country hepatitis policies for harm reduction and HCV testing and treatment in PWID and people in prisons. It aims to capture how governments are translating the WHO Global health sector strategy on viral hepatitis, 2016-2021 into national plans, and provides a summary of the enablers and barriers to HCV testing and treatment in these populations.